慢性阻塞性肺疾病与支气管哮喘患者的气道可逆性分析

肺功能检测是判断气流受限重复性较好的客观指标,也是慢性阻塞性肺疾病（chronic obstructive pulmonary disease,COPD）诊断的核心标准,在COPD的诊断、严重程度评价、疾病进展、预后及治疗反应等方面具有重要意义。支气管舒张试验,反映了气道的“可逆性”,曾经是作为诊断支气管哮喘的重要指标,通常用于支气管哮喘和COPD的鉴别。但随着临床上对该检查方法的深入研究,     

Immunoglobulin G subclasses and spirometry in patients with chronic obstructive pulmonary disease.

Immunoglobulin G (IgG) subclass levels were measured in 58 patients with chronic obstructive pulmonary disease (COPD) and in 125 healthy controls. Total IgG values were significantly lower in the 27 COPD patients on steroid therapy compared with patients not taking steroids (8.31 (0.14) vs 9.80 (0.14), p less than 0.05), geometric mean (log SD). Total IgG (9.80 (0.14) vs 12.18 (0.16), p less than 0.005), IgG1 (5.87 (0.19) vs 6.68 (0.12), p less than 0.05) and IgG2 levels (2.75 (0.21) vs 3.70 (0.20), p less than 0.005) were significantly reduced in the COPD patients not taking steroids compared with the controls. IgG3 values were significantly elevated in smokers compared with nonsmokers in both the control and COPD groups. Fifteen COPD patients (25.9%) had a low level of one or more subclasses. IgG2 subclass deficiency was the most common, being present in 9 patients. A significant correlation was found between forced expiratory volume in one second (FEV1) and IgG2 subclass levels (r = 0.415; p less than 0.005). IgG subclass deficiencies may contribute to the development and progression of respiratory disease in COPD patients.     

Sleep in patients with asthma and chronic obstructive pulmonary disease

Sleep abnormalities are common in patients with asthma and chronic obstructive pulmonary disease. Recent studies have provided new insight into the mechanisms involved in circadian changes in airway resistance, analyzed the effect of disease treatment on sleep quality, and re-examined issues relating to oxygen supplementation at night in patients with chronic obstructive pulmonary disease. Although providing new and useful information, some of these studies also raise new questions that will need answering in the future. This article reviews our current understanding of the complex interactions between sleep and lung disease in patients with asthma and chronic obstructive pulmonary disease.     

不同指标对老年严重慢性阻塞性肺疾病患者吸入支气管舒张剂疗效的评价

目的 对评价严重慢性阻塞性肺疾病(COPD)患者吸入支气管舒张剂疗效的3种指标进行比较. 方法 吸人复方异丙托溴胺溶液前后对18例稳定期严重COPD患者行肺通气功能和肺容量测定,并采用呼气负压技术同步检测呼气流速受限(EFL). 结果 与安慰剂比较,吸入支气管舒张剂后COPD患者第1秒用力呼气容积占预计值(FEV1)百分比、用力肺活量占预计值(FVC)百分比、深吸气量占预计值(IC)百分比显著改善,残气量占预计值(RV)百分比和功能残气量占预计值(FRC)百分比显著降低,肺总量占预计值(TLC)百分比无显著改变;Borg呼吸困难评分显著降低;5分法EFL评分无显著改变,呼吸方式无显著改变.IC、FEV,和5分法EFL评分的平均改善率分别是(20.42±15.02)%、(10.98±7.28)%和(5.15±11.24).△IC与ABorg呈负相关(r=0.732,P<0.05),AFEVl与ABorg相关关系无统计学意义(r=0.343,P>0.05).应用受试者工作特征曲线方法分析3种不同指标诊断呼吸困难的价值,结果表明,IC、FEV1和5分法EFL评分的曲线下面积分别为0.868、0.681和0.557. 结论 与FEV1相比,IC评价严莺COPD患者支气管舒张剂疗效更为灵敏和准确,5分法EFL评分不宜作为评价严重COPD患者吸人支气管舒张剂疗效的指标.     

重视慢性阻塞性肺疾病肺功能诊断中的问题

2007年9月,Am J Respir Crit Care Med发表了最新版本的"全球慢性阻塞性肺疾病防治创议(GOLD)"[1],并配发了3位意大利学者联合署名的述评"COPD指南--重要的是不断提出问题",该文章的题目十分耐人寻味.每年发表的新版本GOLD所充实的内容都来自新近发表的循证医学成果,使GOLD在更新中不断完善,但一些悬而未决抑或存有争议的问题依然存在,还需要更丰富的循证医学资料和进一步研究才能得出更准确的结论.在2007年版GOLD中,仍然延用任何年龄的肺功能均为FEV1/FVC<70%的标准,并以此作为诊断COPD的金标准,笔者不禁提出疑问:该诊断标准合理吗?     

Biomarkers for differentiation of patients with asthma and chronic obstructive pulmonary disease

Objective: Asthma and chronic obstructive pulmonary disease (COPD) are airflow limitation diseases with similar clinical manifestations but different pathophysiologic mechanisms. To implement the appropriate treatment, it is important to distinguish between asthma and COPD which sometimes might result difficult in clinical practice. We evaluated biomarkers to distinguish between asthma and COPD. Methods: Blood eosinophil counts and fractional exhaled nitric oxide (FeNO) levels were analyzed. Serum periostin, interleukin-25 (IL-25), and immunoglobulin E (IgE) concentrations were compared between patients with asthma (n = 60), including atopic-asthma (n = 30) and non-atopic asthma (n = 30), and patients with COPD (n = 30). Results: Significantly higher peripheral blood eosinophil counts (p < 0.001), FeNO levels (p < 0.001), and total serum IgE (P = 0.003) concentrations, but not serum periostin (p = 0.584) or serum IL-25 (p = 0.085) concentrations, were detected in patients with asthma compared to patients with COPD. Serum periostin and IgE concentrations were increased in patients with atopic-asthma compared with those with non-atopic asthma and COPD (p < 0.05). The FeNO levels were significantly correlated with the peripheral blood eosinophil counts (r = 0.430, p = 0.001) and serum IL-25 concentrations (r = 0.338, p = 0.009) in patients with asthma. The serum periostin concentrations were also correlated with the serum IgE concentrations (r = 0.375, p = 0.003)and FeNO levels (r = 0.291, p = 0.024) in patients with asthma. Asthma patients were effectively differentiated from COPD patients based on the FeNO levels (p < 0.001) and peripheral blood eosinophil counts (p < 0.001). Conclusions: FeNO levels and peripheral blood eosinophil counts were useful biomarkers for distinguishing between patients with asthma and COPD. Serum periostin and IgE concentrations could be biomarkers for atopic asthma.     

Bronchodilator reversibility in Australian adults with chronic obstructive pulmonary disease

Abstract Background and aims: Bronchodilator reversibility (BDR) and inhaled corticosteroid (ICS) use were assessed for volunteers who responded to an advertisement requesting current or ex‐smokers who were experiencing breathlessness to attend for lung function testing. Methods: One hundred and fifty‐four volunteers responded. Forced expiratory volume (FEV₁) was measured before and after 400 µg of salbutamol. Significant BDR was assessed according to guidelines of: (i) the American Thoracic Society (≥12% plus 200 mL of baseline FEV₁ or forced vital capacity), (ii) the British ­Thoracic Society (BTS) (≥15% plus 200 mL of baseline FEV₁), (iii) the European Thoracic Society (≥10% predicted FEV₁), and (iv) the most commonly used criteria in Australia and New Zealand (≥15% of baseline FEV₁). Results: One hundred and twenty‐three subjects (33 female; 40 current smokers; median pack years 48 (range 5?144)) were suitable for analysis (i.e. had no history of asthma, demonstrable airflow limitation and a forced expiratory ratio (FER) of <70%). Twenty (16%) patients had an FEV₁ within the normal range but FER of <70%, 24 (20%) patients had mild disease (FEV₁ 60?80% predicted), 31 (24%) patients had moderate disease (FEV₁ 40?59% predicted), and 48 (39%) patients had severe disease (FEV₁ <40% predicted), according to BTS criteria. Significant BDR was evident in: (i) 58 (47%) subjects by American criteria, (ii) 26 (21%) subjects by British criteria, (iii) 19 (15%) subjects by European criteria and (iv) 36 (29%) subjects by Australasian criteria. ICS use was reported by 71 (58%) subjects overall and was weakly, but significantly, related to poorer FEV₁ (r = ?0.2; P < 0.01), and greater BDR (r = 0.3; P < 0.005). Conclusion: Chronic obstructive pulmonary disease in Australian volunteers with no history of asthma encompasses many individuals with significant BDR. Interestingly, most volunteers reported ICS use and this was related to poorer spirometry and greater BDR. However, until the underlying immuno­pathology has been determined they cannot be assumed to have ‘asthma’ or even an ‘asthmatic element’. (Intern Med J 2003; 33: 572?577)     

Inhaled insulin in patients with asthma and chronic obstructive pulmonary disease

The effect of inhaled insulin in subjects with diabetes and chronic lung disease, such as asthma or chronic obstructive pulmonary disease (COPD), is of particular interest because these diseases are quite common, and it is likely that patients with asthma or COPD who are poorly controlled on oral agents and are reluctant to start subcutaneous insulin would benefit from inhaled insulin to improve their glucose control. Since patients with asthma or COPD have varied pulmonary symptoms and abnormal pulmonary function, it is important to establish the pulmonary safety and efficacy of inhaled insulin in subjects with diabetes and asthma or COPD. Pharmacokinetic and pharmacodynamic studies in non-diabetic subjects with asthma consistently show lower absorption of inhaled insulin and lesser glucose lowering effects by approximately 30-40%, as compared to subjects without asthma. Thus, it would be expected that the dose of insulin required to obtain equivalent glycemic control would be higher by approximately 30-40% in subjects with asthma and diabetes (as compared to subjects without asthma but with diabetes). However, prior administration of a bronchodilator inhaler in individuals with asthma and diabetes reverses airway obstruction and thus may obviate the need for increased insulin requirements. In contrast to patients with asthma, in patients with COPD and diabetes, the absorption of inhaled insulin appears to be variable (higher or lower than in non-COPD subjects). Whether this variability is secondary to differences in inhalation devices or different study populations is not clear at present. Overall, data from the clinical studies indicate that inhaled insulin is effective and well tolerated in subjects with diabetes and chronic lung disease. However, preliminary, limited data from the longer-term clinical studies suggest that there is a marginally greater decline in pulmonary function tests in subjects with asthma/COPD and diabetes compared to subjects with diabetes and no chronic lung disease. Thus, there is a clear need for longer-term studies in subjects with diabetes and chronic lung disease in order to further clarify the safety and efficacy of inhaled insulin in this population.     

Physical training and testing in patients with chronic obstructive pulmonary disease

Introduction: The effects of different training modes need to be investigated further in patients with chronic obstructive pulmonary disease (COPD). Both advanced laboratory tests and field tests are used in patients with COPD to evaluate effects of interventions such as pulmonary rehabilitation. Aims: The overall aims of the studies were to investigate the effects of different training modalities on exercise capacity and on health‐related quality of life (HRQoL) in patients with moderate or severe COPD and, further, to explore two of the physical field tests used in pulmonary rehabilitation, the 12‐min walk test and the incremental shuttle walking test (ISWT). Materials and Methods: Patients with moderate or severe COPD were included. In study I (n = 57), the 12‐min walk test was performed three times within 1 week. Exercise‐induced hypoxemia (EIH) was assessed by pulse oximeter and was defined as SpO₂ < 90%. In study II (n = 93), performance on ISWT was compared to performance on two different cycle tests. In study III (n = 42), the effects of two different combination training programmes were compared when training twice a week for 8 weeks. One programme was mainly based on endurance training (group A), and the other was based on resistance training and on callisthenics (group B). In study IV (n = 60), endurance training with interval resistance was compared to endurance training with continuous resistance. Results: In study I, the 12‐min walking distance (12MWD) did not increase on retesting in patients with EIH, but increased significantly on retesting in the non‐EIH patients. In study II, the ISWT was as good a predictor of peak exercise capacity (W peak) as peak oxygen uptake (VO₂ peak) was. In study III, W peak and 12MWD increased in group A but not in group B. HRQoL, anxiety and depression were unchanged in both groups. Ratings of perceived exertion at rest were significantly lower in group A than in group B after training and during 12 months of follow‐up. Twelve months post training, 12MWD was back to baseline in group A, but was significantly shorter than at baseline in group B. Patients with moderate and severe COPD responded to training in the same way. In study IV, both interval and continuous endurance training increased W peak, VO₂ peak, peak exhaled carbon dioxide (VCO₂ peak) and 12MWD. Likewise, HRQoL, dyspnoea during activities of daily life, anxiety and depression improved similarly in both groups. At a fixed, sub‐maximal workload (isotime), the interval training reduced oxygen cost and ventilatory demand significantly more than the continuous training did. Conclusions: EIH affects the retest effects on 12MWD. W peak can be predicted from an ISWT similarly well as from VO₂ peak. A short training programme can improve W peak and 12MWD when based mainly on endurance training. Both patients with moderate and severe COPD respond to training in the same way. A short endurance training intervention can possibly delay decline in 12MWD for 1 year. Both interval and continuous endurance training improves physical performance and HRQoL. Interval training lowers the energy cost of sub‐maximal work more than continuous training does.     

Prevalence of gastroesophageal reflux disease in patients with asthma and chronic obstructive pulmonary disease

Background and Aim: It is speculated that the prevalence of gastroesophageal reflux disease (GERD) might increase with asthma or chronic obstructive pulmonary disease (COPD). The aim of the present study was to evaluate the prevalence of GERD in patients with asthma and COPD in an area representative of developing countries. Methods: A validated GERD questionnaire was conducted face‐to‐face with 308 consecutive asthma (240 women) and 133 COPD (35 women) patients in the tertiary referral pulmonary outpatient clinic, and 694 controls from the research area. Detailed histories of patients and pulmonary function tests were also recorded. Results: The prevalence of GERD (heartburn/regurgitation once a week or more) was 25.4%, 17.0%, 19.4% and occasional symptoms (less than weekly) were 21.2%, 16.3% and 27.0% of patients with asthma, COPD and controls, respectively. The prevalence was higher in the asthma group compared with the controls and the COPD group. No significant difference was found between the COPD group and the controls. Heartburn started following pulmonary disease in 24.1% of the asthma group, and 26.4% of the COPD group. The majority of additional symptoms were significantly higher in asthmatics compared with the controls. No difference was found in the consumption of pulmonary medications in asthmatic patients in groups with different symptom frequency. Heartburn was increased 13.8% by the consumption of inhaler medications. Conclusions: These results implicate that the prevalence of GERD in asthma and COPD are lower than in published reports in a tertiary referral center. These differences might be related to the characteristics of developing countries, increased consumption of powerful medications in GERD and pulmonary diseases, or methodological flaws in earlier studies.     

慢性阻塞性肺疾病肺康复治疗进展及实践

已证实肺康复能有效地减轻慢性阻塞性肺疾病(COPD)患者的呼吸困难,提高运动耐力和健康相关生活质量。不同严重程度的COPD患者均可从肺康复中受益。其内容主要包括运动锻炼、吸气肌肉训练、营养疗法等,运动锻炼是肺康复的核心内容。近年来,提高肺康复效果的方法有了新发展,主要包括增加运动量、教育管理和心理支持。虽然肺康复传统地应用于稳定期COPD患者,但对于AECOPD患者,感染控制后就可开始早期肺康复。肺康复应当遵循运动量的最大化,并个体化和联合不同方法。     

Physical activity, spirometry and quality-of-life in chronic obstructive pulmonary disease

Chronic obstructive pulmonary disease (COPD) has a high level of morbidity. There is limited information about levels of physical activity among community dwelling subjects with the disease and its association with lung function and quality of life. In this study, 176 subjects with COPD were recruited from general practices. Physical activity was measured over 7 days using pedometers, quality-of-life using the St. George's Respiratory Questionnaire, and lung function using spirometry, 124 subjects, 60% male, aged 70 +/- 8 years were included in the analysis. Physical activity levels were low, median steps/day for males = 3621, IQR = 4247 and for females = 4287, IQR = 3063. Overall physical activity (median steps/day = 3716, IQR = 3682) was significantly associated with the forced expiratory volume in one second (r = 0.39, p < 0.001) and with St. George's Respiratory Questionnaire score (r = -0.28, p < 0.01). In conclusion, we have demonstrated that in a community-based sample of people with COPD, daily physical activity levels were low compared with usual levels reported for the general population. Physical activity was significantly associated with disease severity, measured by lung function, and quality-of-life.     

Remodeling in asthma and chronic obstructive pulmonary disease

Airway and lung tissue remodeling and fibrosis play an important role in the development of symptoms associated with lung function loss in asthma and chronic obstructive pulmonary disease (COPD). In the past decades, much attention has been paid to the inflammatory cellular process involved in airway remodeling in these two diseases. However, it is increasingly clear that resident cells contribute to airway and lung tissue remodeling and to associated fibrosis as well. This article deals with some new aspects and discusses the role of vasculature and vascular endothelial growth factor in the development of airway obstruction and airway wall fibrosis in asthma and COPD. Moreover, it addresses the extracellular matrix (ECM) turnover as present in both asthma and COPD. All components of lung ECM (collagen, elastic fibers, proteoglycans) have been shown to be potentially altered in these two diseases. Finally, the interaction between transforming growth factor (TGF), Smad signaling, and TGF in the ECM turnover will be discussed. We propose that ECM damage and repair contribute to airway and lung tissue pathology and that the vasculature may enhance this process. The localization of this process is dependent on the etiology of the disease (i.e., allergen-driven in asthma and smoke-driven in COPD) and the local environment in which the pathologic process takes place.     

Pulmonary exercise testing predicts prognosis in patients with chronic obstructive pulmonary disease

OBJECTIVE: In patients with chronic obstructive pulmonary disease (COPD), patient age and initial value of forced expiratory volume in 1 second (FEV1) have been considered the most accurate predictors of mortality among the parameters obtained from pulmonary exercise tests. However, few studies have examined the predictive variables of prognosis among exercise parameters in COPD. We therefore attempted to identify the best index for predicting long-term survival in patients with COPD among the cardiopulmonary variables obtained during exercise testing. PATIENTS AND METHODS: Fifty-eight patients with COPD (50 men and 8 women) without hypoxemia at rest or other serious complications performed resting pulmonary function tests followed by a symptom-limited ramp exercise test on a cycle ergometer with breath-by-breath gas analysis and arterial blood gas sampling. RESULTS: After 3,570+/-1,373 days follow-up (mean+/-SD), 21 died because of deaths by respiratory failure. The overall survival rates calculated by the Kaplan-Meier method were 92.9% and 75.8% at 5 years and 10 years, respectively. In univariate Cox hazards analysis, age, FEV1, VC, RV/TLC, VEmax, VO2max, VCO2max, PaO2max, PacO2max, and PaO2 at rest were found to be significant prognostic indices of survival. However, multivariate analysis revealed only FEV1, PaO2max, and age as independent predictors of mortality. In severe COPD patients (FEV1 <50% predicted, n=35), PaO2max and age also correlated with prognosis, whereas FEV1 did not. CONCLUSION: Pulmonary exercise testing is useful in predicting prognosis in patients with COPD.     

长期家庭氧疗对缓解期COPD患者的影响研究

目的观察长期家庭氧疗对缓解期COPD患者的肺功能及血气影响。方法选择60例缓解期COPD患者随机分为两组,笫1组单纯家庭氧疗（每天15小时以上）,笫2组不给予氧疗,1年后观察两组FEV1%预计值、血气的变化情况。结果氧疗组FEV1%预计值、动脉血氧分压明显高于对照组（P〈0.01）。结论长期家庭氧疗可以改善COPD患者的动脉血氧分压和肺功能。     

Overlap of asthma and chronic obstructive pulmonary disease

PURPOSE OF REVIEW: Asthma and chronic obstructive pulmonary disease (COPD) are both defined by the presence of airflow obstruction, but they present distinguishing differences in terms of both risk factors and clinical phenotypes. Yet it is quite common in the clinical setting to observe patients with asthma showing COPD-like phenotypes, and vice versa, making it a priority to search for optimal prevention, treatment, and management strategies for these cases of coexisting lung obstructive diseases. RECENT FINDINGS: Recent studies have provided further evidence of strong epidemiologic and clinical links between asthma and COPD. Adult subjects with active asthma are as much as 12 times more likely to acquire COPD over time than subjects with no active asthma. Signs identifying patients with asthma predisposed to developing COPD may already be present at the early stages of the disease, a finding with potential implications for prevention of COPD. In addition to spirometry and other pulmonary function tests (such as measurements of residual volume and diffusing capacity of the lung for carbon monoxide), recent evidence suggests that the assessment of type and degree of airway remodeling and the evaluation of inflammatory markers might prove useful in the future to characterize phenotypically patients with coexisting asthma and COPD. SUMMARY: The nature of the association between asthma and COPD remains unclear and open to discussion. Further research is required to develop effective management algorithms for patients with multiple obstructive lung diseases, determine to what extent early treatment and optimal management of asthma may protect against progression into COPD, and identify genetic markers of individual susceptibility to specific lung disease phenotypes and pharmacologic treatments.     

老年中、重度慢性阻塞性肺疾病患者气道可逆性比较

目的:探讨老年中、重度慢性阻塞性肺疾病(COPD)患者气道阻塞的可逆性,并进行比较。方法:入选46例老年中度COPD稳定期患者和42例老年重度COPD稳定期患者,测定其吸入硫酸沙丁胺醇前后肺通气功能,观察各通气指标改善情况,计算改善率并进行比较。结果:中度COPD组和重度COPD组患者吸药后的肺功能均有一定改善,但重度COPD患者的呼气峰流速(PEF)、一秒钟用力呼气量(FEV1)、最大呼气中段流量(MEF25-75)等指标的改变率显著小于中度COPD组(P<0.05);重度COPD患者中有4.76%支气管舒张试验阳性,而中度COPD患者中36.96%支气管舒张试验阳性。结论:部分COPD患者气道阻塞具有一定可逆性,但老年重度COPD患者的气道可逆程度明显低于老年中度COPD患者。     

The validity of the diagnosis of chronic obstructive pulmonary disease in general practice.

AIM: To determine the validity of the diagnosis of chronic obstructive pulmonary disease (COPD) in general practice in patients given a diagnosis of COPD and treated with bronchodilators. METHODS: From the medical records of eight Health Centres in Northern Greece, 319 subjects aged over 40 years and diagnosed as "COPD" were entered into the study. All filled in a special questionnaire and were subjected to spirometry, rhinomanometry and chest X-ray. RESULTS: One hundred and sixty patients (50.2%) met the GOLD criteria for COPD. Twenty-six of them were non-smokers and underwent further evaluation: blood eosinophil count, serum IgE assay, high resolution computed tomography (HRCT) scan of the chest, and echocardiography; 16 were given a different diagnosis. One hundred and fifty-nine subjects (49.8%) with an FEV1/ FVC ratio >0.7 did not meet the GOLD criteria for COPD; 71 suffered from nasal obstruction, 13 from asthma, six had restrictive pulmonary disease and 69 had no respiratory disease. CONCLUSION: Diagnostic errors in patients with respiratory symptoms in the primary healthcare setting are frequent. Patients suspected to have COPD should undergo spirometry testing after bronchodilation. An alternative diagnosis must be sought for non-smoking patients with irreversible airway obstruction.     

Comparison of serum biomarkers between patients with asthma and with chronic obstructive pulmonary disease

Objective: Asthma and chronic obstructive pulmonary disease (COPD) have distinct pathophysiological mechanisms but sometimes share similar clinical manifestations. Distinguishing between these diseases is important. This study compared the profiles of serum biomarkers between patients with asthma and those with COPD. Methods: Serum levels of the chitinase like protein YKL-40, periostin, interleukin (IL)-18, and chemokine (C--C motif) ligand 18 (CCL18) were measured in asthma patients (n = 20), COPD patients (n = 16), and normal controls (n = 20). Results: Serum levels of YKL-40 were higher in COPD patients [median (range), 55 (17–565) versus 208 (74–922) ng/mL, p < 0.0001], but no differences were observed between asthma and COPD patients after adjusting for age and forced expiratory volume in 1 s (FEV₁). No differences in serum levels of periostin, IL-18, or CCL18 were observed between the patient groups. Total IgE and airway hypersensitivity were negatively correlated (r = ?0.485, p = 0.007). CCL18 levels were related to patients’ age in asthmatic patients (r = ?0.562, p = 0.010). Serum levels of CCL18 and IL-18 were positively correlated in patients with COPD (r = 0.696, p = 0.003). Conclusions: No differences in the serum profiles of periostin, IL-18, or CCL18 were observed between patients with asthma and those with COPD. Serum levels of YKL-40 were not different between asthma and COPD patients after adjusting for age and FEV₁. There were negative correlation between CCL18 and age in patients with asthma and positive correlation between IL-18 and CCL18 in patients with COPD.     

Rehabilitation for patients with chronic obstructive pulmonary disease

OBJECTIVE: To develop a meta-analysis to determine the effectiveness of rehabilitation in patients with chronic obstructive pulmonary disease (COPD). DATA SOURCES: medline, cinhal, and Cochrane Library searches for trials of rehabilitation for COPD patients. Abstracts presented at national meetings and the reference lists of pertinent articles were reviewed. STUDY SELECTION: Studies were included if: trials were randomized; patients were symptomatic with forced expiratory volume in one second (FEV1) <70% or FEV1 divided by forced vital capacity (FEV1/FVC) <70% predicted; rehabilitation group received at least 4 weeks of rehabilitation; control group received no rehabilitation; and outcome measures included exercise capacity or shortness of breath. We identified 69 trials, of which 20 trials were included in the final analysis. DATA EXTRACTION: Effect of rehabilitation was calculated as the standardized effect size (ES) using random effects estimation techniques. RESULTS: The rehabilitation groups of 20 trials (979 patients) did significantly better than control groups on walking test (ES = 0.71; 95% confidence interval [95% CI], 0.43 to 0.99). The rehabilitation groups of 12 trials (723 patients) that used the Chronic Respiratory Disease Questionnaire had less shortness of breath than did the control groups (ES = 0.62; 95% CI, 0.35 to 0.89). Trials that used respiratory muscle training only showed no significant difference between rehabilitation and control groups, whereas trials that used at least lower-extremity training showed that rehabilitation groups did significantly better than control groups on walking test and shortness of breath. Trials that included severe COPD patients showed that rehabilitation groups did significantly better than control groups only when the rehabilitation programs were 6 months or longer. Trials that included mild/moderate COPD patients showed that rehabilitation groups did significantly better than control groups with both short- and long-term rehabilitation programs. CONCLUSION: COPD patients who receive rehabilitation have a better exercise capacity and they experience less shortness of breath than patients who do not receive rehabilitation. COPD patients may benefit from rehabilitation programs that include at least lower-extremity training. Patients with mild/moderate COPD benefit from short- and long-term rehabilitation, whereas patients with severe COPD may benefit from rehabilitation programs of at least 6 months.